{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:40:13Z","timestamp":1787010013971,"version":"build-2736575974"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>\n                      To analyze the effects of a dexamethasone intravitreal implant (DEX; Ozurdex 700\n                      <jats:italic toggle=\"yes\">\u03bc<\/jats:italic>\n                      g; Allergan) administered immediately after cataract surgery in diabetic patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This prospective, single-arm, open label study (NCT01748487 at ClinicalTrials.gov) involved Type 2 diabetic patients with at least mild diabetic retinopathy (DR) who underwent cataract surgery and DEX insertion after phacoemulsification, and intraocular lens implantation were enrolled. Best-corrected visual acuity and central retinal thickness (CRT) measured by spectral-domain optical coherence tomography were recorded at 1 week preoperatively, and 1 week, 1 month, and 3 months after surgery. Adverse events were also recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Twenty-four eyes of 24 patients (17 [70.8%] men; mean age 63.7 \u00b1 8.7 years) with mild nonproliferative DR (41.7%), moderate nonproliferative DR (33.3%), severe nonproliferative DR (16.7%), or treated proliferative DR (8.3%) were selected. After DEX treatment, mean CRT changed from 241.1\n                      <jats:italic toggle=\"yes\">\u03bc<\/jats:italic>\n                      m (95% confidence interval, 227.5\u2013254.6\n                      <jats:italic toggle=\"yes\">\u03bc<\/jats:italic>\n                      m) at baseline to 236.9\n                      <jats:italic toggle=\"yes\">\u03bc<\/jats:italic>\n                      m (95% confidence interval, 223.9\u2013249.9\n                      <jats:italic toggle=\"yes\">\u03bc<\/jats:italic>\n                      m) at 1 week (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.09), 238.9\n                      <jats:italic toggle=\"yes\">\u03bc<\/jats:italic>\n                      m (95% confidence interval, 225.5\u2013252.3\n                      <jats:italic toggle=\"yes\">\u03bc<\/jats:italic>\n                      m) at 1 month (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.44), and 248\n                      <jats:italic toggle=\"yes\">\u03bc<\/jats:italic>\n                      m (95% confidence interval, 232.4\u2013260.8\n                      <jats:italic toggle=\"yes\">\u03bc<\/jats:italic>\n                      m) at 3 months (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.15). No eyes showed a postoperative increase &gt;50\n                      <jats:italic toggle=\"yes\">\u03bc<\/jats:italic>\n                      m in the CRT at any visit. A 10% increase in CRT was found in 8.3% of eyes. Mean best-corrected visual acuity significantly improved from 0.37 (20\/50) at baseline to 0.19 (20\/30) at 1 week, 0.12 (20\/25) at 1 month, and 0.12 (20\/25) at 3 months (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001 for each comparison). Mean intraocular pressure before surgery was 13.8 mmHg, and none of the patients developed an intraocular pressure \u226522 mmHg at any visit. None of the patients developed any serious adverse events during the follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>These short-term results suggest that a single DEX injection intraoperatively after phacoemulsification could avoid an increase in CRT after cataract surgery in diabetic patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000001552","type":"journal-article","created":{"date-parts":[[2017,2,11]],"date-time":"2017-02-11T09:48:49Z","timestamp":1486806529000},"page":"490-496","source":"Crossref","is-referenced-by-count":35,"title":["EFFECT OF AN INTRAVITREAL DEXAMETHASONE IMPLANT ON DIABETIC MACULAR EDEMA AFTER CATARACT SURGERY"],"prefix":"10.1097","volume":"38","author":[{"given":"Pilar","family":"Calvo","sequence":"first","affiliation":[{"name":"IIS-Aragon, Ophthalmology Department, Miguel Servet University Hospital, Zaragoza, Spain;"},{"name":"University of Zaragoza, Zaragoza, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ferreras","sequence":"additional","affiliation":[{"name":"IIS-Aragon, Ophthalmology Department, Miguel Servet University Hospital, Zaragoza, Spain;"},{"name":"University of Zaragoza, Zaragoza, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadwa","family":"Al Adel","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wantanee","family":"Dangboon","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Brent","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20230816","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/S0161-6420(84)34102-1","article-title":"The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema","volume":"91","author":"Klein","year":"1984","journal-title":"Ophthalmology"},{"key":"R3-20230816","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1001\/archopht.1985.01050120030015","article-title":"Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group","volume":"103","year":"1985","journal-title":"Arch Ophthalmol"},{"key":"R4-20230816","first-page":"761","article-title":"Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 2. Early Treatment Diabetic Retinopathy Study research group","volume":"94","year":"1987","journal-title":"Ophthalmology"},{"key":"R5-20230816","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00417-008-0935-z","article-title":"Lutein prevents cataract development and progression in diabetic rats","volume":"247","author":"Arnal","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R6-20230816","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.exer.2008.08.001","article-title":"Synergistic effect of osmotic and oxidative stress in slow-developing cataract formation","volume":"87","author":"Chan","year":"2008","journal-title":"Exp Eye Res"},{"key":"R7-20230816","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.ophtha.2006.08.053","article-title":"Analysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomography","volume":"114","author":"Kim","year":"2007","journal-title":"Ophthalmology"},{"key":"R8-20230816","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00347-003-0982-0","article-title":"Intravitreal triamcinolone acetonide for the treatment of intraocular edematous and neovascular diseases [in German]","volume":"101","author":"Jonas","year":"2004","journal-title":"Ophthalmologe"},{"key":"R9-20230816","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0181-5512(05)80988-X","article-title":"Intravitreal injection of triamcinolone acetonide for the treatment of macular edema [in French]","volume":"28","author":"Ladjimi","year":"2005","journal-title":"J Fr Ophthalmol"},{"key":"R10-20230816","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1600-0420.2004.00336.x","article-title":"Intravitreal triamcinolone for macular oedema: efficacy in relation to aetiology","volume":"83","author":"Sorensen","year":"2005","journal-title":"Acta Ophthalmol Scand"},{"key":"R11-20230816","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/112067210501500114","article-title":"Intravitreal triamcinolone acetonide in refractory pseudophakic cystoid macular edema: functional and anatomic results","volume":"15","author":"Boscia","year":"2005","journal-title":"Eur J Ophthalmol"},{"key":"R12-20230816","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","article-title":"Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"117","author":"Elman","year":"2010","journal-title":"Ophthalmology"},{"key":"R13-20230816","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/j.ophtha.2009.04.023","article-title":"Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study","volume":"116","author":"Nguyen","year":"2009","journal-title":"Ophthalmology"},{"key":"R14-20230816","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1097\/IAE.0b013e318176de48","article-title":"Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema","volume":"28","author":"Kook","year":"2008","journal-title":"Retina"},{"key":"R15-20230816","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.ophtha.2009.01.014","article-title":"Analysis of the effect of intravitreal bevacizumab injection on diabetic macular edema after cataract surgery","volume":"116","author":"Takamura","year":"2009","journal-title":"Ophthalmology"},{"key":"R16-20230816","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/eye.2008.2","article-title":"Intravitreal pegaptanib sodium for refractory pseudophakic macular oedema","volume":"22","author":"Cervera","year":"2008","journal-title":"Eye (Lond)"},{"key":"R17-20230816","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/ICU.0b013e328329b656","article-title":"Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration","volume":"20","author":"Jeganathan","year":"2009","journal-title":"Curr Opin Ophthalmol"},{"key":"R18-20230816","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1007\/s00125-008-0989-9","article-title":"Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy","volume":"51","author":"Simo","year":"2008","journal-title":"Diabetologia"},{"key":"R19-20230816","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09273940701246314","article-title":"Are intravitreal anti-VEGF antibodies safe?","volume":"15","author":"Tezel","year":"2007","journal-title":"Ocul Immunol Inflamm"},{"key":"R20-20230816","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology"},{"key":"R21-20230816","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/archopht.125.3.309","article-title":"Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema","volume":"125","author":"Kuppermann","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"R22-20230816","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/archopht.1993.01090060119035","article-title":"The lens Opacities Classification System III. The Longitudinal Study of Cataract Study Group","volume":"111","author":"Chylack","year":"1993","journal-title":"Arch Ophthalmol"},{"key":"R23-20230816","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0161-6420(03)00475-5","article-title":"Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales","volume":"110","author":"Wilkinson","year":"2003","journal-title":"Ophthalmology"},{"key":"R24-20230816","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","article-title":"Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion","volume":"117","author":"Haller","year":"2010","journal-title":"Ophthalmology"},{"key":"R25-20230816","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ophtha.2012.08.002","article-title":"Dexamethasone intravitreal implant during phacoemulsication","volume":"120","author":"Agarwal","year":"2013","journal-title":"Ophthalmology"},{"key":"R26-20230816","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ophtha.2013.06.033","article-title":"Dexamethasone implant anterior chamber migration: risk factors, complications, and management strategies","volume":"121","author":"Khurana","year":"2014","journal-title":"Ophthalmology"},{"key":"R27-20230816","doi-asserted-by":"crossref","first-page":"168","DOI":"10.5301\/ejo.5000523","article-title":"Use of intravitreal dexamethasone implant in patients with cataract and macular edema undergoing phacoemulsification","volume":"25","author":"Sze","year":"2015","journal-title":"Eur J Ophthalmol"},{"key":"R28-20230816","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3928\/23258160-20150101-09","article-title":"Dexamethasone intravitreal implant for pseudophakic cystoid macular edema in patients with diabetes","volume":"46","author":"Khurana","year":"2015","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R29-20230816","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1001\/jamaophthalmol.2013.2313","article-title":"Macular edema after cataract surgery in eyes without preoperative central-involved diabetic macular edema","volume":"131","author":"Baker","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"R30-20230816","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ophtha.2015.10.001","article-title":"Risk factors and incidence of macular edema after cataract surgery: a database study of 81984 eyes","volume":"123","author":"Chu","year":"2016","journal-title":"Ophthalmology"},{"key":"R31-20230816","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jcrs.2006.03.039","article-title":"Nonproliferative diabetic retinopathy and macular edema progression after phacoemulsification: prospective study","volume":"32","author":"Romero-Aroca","year":"2006","journal-title":"J Cataract Refract Surg"},{"key":"R32-20230816","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/ICU.0b013e32834cd5f8","article-title":"Pseudophakic cystoid macular edema","volume":"23","author":"Yonekawa","year":"2012","journal-title":"Curr Opin Ophthalmol"},{"key":"R33-20230816","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ajo.2015.10.005","article-title":"Prevention of cystoid macular edema after cataract surgery in non-diabetic and diabetic patients: a systematic review and meta-analysis","volume":"161","author":"Kim","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"R34-20230816","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1001\/archopht.1992.01080140115038","article-title":"Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection","volume":"110","author":"Kwak","year":"1992","journal-title":"Arch Ophthalmol"},{"key":"R35-20230816","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1167\/iovs.10-5285","article-title":"Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant","volume":"52","author":"Chang-Lin","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R36-20230816","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1167\/iovs.10-6387","article-title":"Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes","volume":"52","author":"Chang-Lin","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R37-20230816","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40123-013-0020-5","article-title":"Intraocular pressure effects of common topical steroids for post-cataract inflammation: are they all the same?","volume":"2","author":"Pleyer","year":"2013","journal-title":"Ophthalmol Ther"},{"key":"R38-20230816","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jcrs.2010.10.051","article-title":"Risk factors for steroid response among cataract patients","volume":"37","author":"Chang","year":"2011","journal-title":"J Cataract Refract Surg"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006982-201803000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T20:11:55Z","timestamp":1692216715000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201803000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000001552","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]}}}